Hana Biosciences receives orphan drug designation for cancer drug Ropidoxuridine
Hana Biosciences announced that the U.S. food and Drug Administration has granted Orphan Drug Designation for Ropidoxuridine (IPdR) for the treatment of malignant glioma, which makes up approximately half of all primary brain tumors. Ropidoxuridine is a orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in phase II studies in anaplastic astrocytoma, a type of brain tumor. Hana Biosciences also recently received orphan drug designation for Talotrexin for the treatment of acute lymphoblastic leukemia.
"This designation not only underscores the need for improved therapies in malignant glioma, it also reiterates the company's development strategy in areas of unmet need. Hana Biosciences is committed to the clinical development of Ropidoxuridine in this disease," commented Greg Berk, MD, Senior Vice President and Chief Medical Officer of Hana Biosciences.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.